Ian M.Pearson

Associate

San Francisco + 1.415.875.5791 Washington + 1.202.879.3404

Ian Pearson's practice focuses on food and drug law. Ian advises clients across a range of U.S. Food & Drug Administration (FDA)-regulated sectors, including medical devices, drugs, biologics, and cosmetics

Though his FDA experience is broad and varied, Ian has a distinct focus on the evolving digital health sector and has counseled clients on numerous matters involving mobile medical applications, clinical decision support software, diagnostic algorithms, and other types emerging digital and remote-use devices used for, or complementary to, the delivery of health care services. Ian's FDA work includes advising FDA-regulated companies at the planning, regulatory submission, and post-marketing stages of product development and commercialization, including matters related to product advertising and promotion, good manufacturing practice requirements, FDA inspection and product recall, and managing enforcement actions, among others.

Before joining Jones Day, Ian served for more than seven years in the FDA's Office of Chief Counsel. During that time he was responsible for providing FDA leadership with legal advice on a wide range of regulatory matters and was an FDA lead in the area of digital health, where he assisted agency officials with the development and implementation of the 21st Century Cures Act and associated guidance clarifying FDA's authority to regulate certain types of medical software. He has significant first-hand experience navigating the complexities of the Federal Food, Drug, and Cosmetic Act (FFDCA), as well as the Administrative Procedure Act, Freedom of Information Act (FOIA), Privacy Act, and provisions of the Public Health Service Act applicable to FDA regulatory matters.

Experience

  • Astellas Pharma to acquire iota BiosciencesJones Day is advising Astellas Pharma Inc. in its acquisition of iota Biosciences.
  • STERIS to acquire Key Surgical for approximately $850 millionJones Day is advising STERIS plc (NYSE: STE) in the $850 million acquisition of Key Surgical, a leading global provider of sterile processing, operating room, and endoscopy products, and a portfolio company of Water Street Healthcare Partners, LLC.
  • Athersys completes $57.6 million public offering of Common StockJones Day represented Athersys, Inc., a clinical-stage biotechnology company developing novel and proprietary best-in-class therapies designed to extend and enhance the quality of human life, in connection with the $57.6 million underwritten public offering of 25,587,500 shares of Common Stock.
  • Morgan Stanley Capital Partners portfolio company acquires iMark MoldingJones Day represented Morgan Stanley Capital Partners in connection with the acquisition and related financing by portfolio company Comar Holding Company, LLC of iMark Molding, LLC ("iMark") from the original iMark founders.
  • Concord Health Partners participates in $25 million investment in Pieces TechnologiesJones Day represented Concord Health Partners LLC in connection with their investment in Pieces Technologies, a healthcare artificial intelligence and technology company that connects health systems and the community to address clinical and social determinants of health.
  • Misonix acquires Solsys Medical, LLC for $109 millionJones Day advised Misonix, Inc. in its acquisition of Solsys Medical, LLC, a privately held regenerative medical company, in an all-stock transaction valued at approximately $109 million.
  • Stedical Scientific acquires PermeaDerm, Inc.Jones Day advised Stedical Scientific in its acquisition of PermeaDerm, Inc.
  • Arsenal Capital Partners acquires HistoGeneX and Caprion BiosciencesJones Day advised Arsenal Capital Partners on major investments in HistoGeneX and Caprion Biosciences and the subsequent combination of the two businesses.
  • Shore Capital Partners portfolio company acquires MD Resource CorpJones Day represented Shore Capital Partners LLC in connection with the acquisition by portfolio company Innovia Medical of Medical Device Resource Corporation, a manufacturer and distributor of liposuction and fat transfer systems for the plastic and cosmetic surgery markets.
  • Koch Disruptive Technologies leads $150 million investment in INSIGHTECJones Day advised Koch Disruptive Technologies, a subsidiary of Koch Industries, Inc. focused on finding and funding innovative and emerging companies, as the lead investor in a $150 million Series E funding round for INSIGHTEC, a commercial stage medical device company.
  • Speaking Engagements

    • October 10, 2018
      DIA Combination Products Conference: Short Course - How the MDR will Affect Combination Products
    • September 26, 2018
      ABA Life Science Legal Summit
    • February 2018
      FDLI/CDRH In-House Training Course: Introduction to US Medical Device Law and Regulation
    We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.